ADMA Biologics, Inc. (ADMA)
9.72
-0.21
(-2.11%)
USD |
NASDAQ |
Oct 02, 16:00
9.72
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Price to Book Value : 5.366 for Oct. 2, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 5.366 |
| October 01, 2026 | 5.482 |
| September 30, 2026 | 5.537 |
| September 29, 2026 | 5.498 |
| September 28, 2026 | 5.587 |
| September 25, 2026 | 5.178 |
| September 24, 2026 | 5.256 |
| September 23, 2026 | 5.355 |
| September 22, 2026 | 5.416 |
| September 21, 2026 | 5.247 |
| September 18, 2026 | 5.029 |
| September 17, 2026 | 4.941 |
| September 16, 2026 | 4.913 |
| September 15, 2026 | 4.753 |
| September 14, 2026 | 5.046 |
| September 11, 2026 | 5.096 |
| September 10, 2026 | 5.184 |
| September 09, 2026 | 5.217 |
| September 08, 2026 | 5.267 |
| September 04, 2026 | 5.311 |
| September 03, 2026 | 5.289 |
| September 02, 2026 | 5.250 |
| September 01, 2026 | 5.151 |
| August 31, 2026 | 5.184 |
| August 28, 2026 | 5.156 |
| Date | Value |
|---|---|
| August 27, 2026 | 5.234 |
| August 26, 2026 | 5.316 |
| August 25, 2026 | 5.366 |
| August 24, 2026 | 5.272 |
| August 21, 2026 | 5.432 |
| August 20, 2026 | 5.388 |
| August 19, 2026 | 5.548 |
| August 18, 2026 | 5.267 |
| August 17, 2026 | 5.156 |
| August 14, 2026 | 5.228 |
| August 13, 2026 | 5.195 |
| August 12, 2026 | 5.399 |
| August 11, 2026 | 5.468 |
| August 10, 2026 | 5.383 |
| August 07, 2026 | 5.465 |
| August 06, 2026 | 5.554 |
| August 05, 2026 | 5.112 |
| August 04, 2026 | 4.919 |
| August 03, 2026 | 4.825 |
| July 31, 2026 | 4.670 |
| July 30, 2026 | 4.786 |
| July 29, 2026 | 4.808 |
| July 28, 2026 | 4.853 |
| July 27, 2026 | 4.682 |
| July 24, 2026 | 4.566 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Vericel Corp. | 5.552 |
| BioMarin Pharmaceutical, Inc. | 1.750 |
| Emergent BioSolutions, Inc. | 0.9512 |
| Exelixis, Inc. | 7.882 |
| Akebia Therapeutics, Inc. | 9.395 |
Price to Book Value Related Metrics
| PE Ratio | 13.80 |
| PS Ratio | 4.548 |
| Price to Free Cash Flow | 20.05 |
| Price | 9.72 |
| Earnings Yield | 7.25% |
| Market Cap | 2.190B |
| Operating PE Ratio | 10.76 |
| Normalized PE Ratio | 13.68 |